Radiotherapy after breast-conserving surgery can be safely omitted in certain older women with low-risk, hormone receptor-positive early breast cancer receiving adjuvant endocrine therapy, 10-year results of the PRIME II trial showed.

Source: The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has recently reached 65,000 participants. Which surpasses the halfway mark toward its current goal of 128,905. Organisers said on Friday that enrolment had doubled over the last year and a half, with Black women accounting for more than 20% of enrolment.